Inactivated bovine herpesvirus 1 marker vaccines are more efficacious in reducing virus excretion after reactivation than a live marker vaccine

Vaccine

Volumn 15, Issue 14, 1997, Pages 1512-1517

  Bosch, J C ^b   Kaashoek, M J ^c   Van Oirschot, J T ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b HG   (Netherlands)

^c INTERVET INTERNATIONAL BV   (Netherlands)

Author keywords

Bovine herpesvirus 1; Marker vaccines; Reactivation; Reexcretion

Indexed keywords

DEXAMETHASONE; INACTIVATED VACCINE; LIVE VACCINE; MARKER;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; BOVINE HERPES VIRUS; CATTLE; CONTROLLED STUDY; HERPES; HERPES SIMPLEX VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRUS EXCRETION; VIRUS REACTIVATION; VIRUS SHEDDING;

ANIMALS; ANTIBODIES, VIRAL; CATTLE; FEMALE; HERPESVIRUS 1, BOVINE; VACCINATION; VACCINES, INACTIVATED; VIRAL VACCINES; VIRUS ACTIVATION;

EID: 0030796536     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00092-3     Document Type: Article

References (31)

1. Pastoret, P.P., Aguilar-Setién, A., Burtonboy, G., Mager, J., Jetteur, P. and Schoenmaers, F. Effect of repeated treatment with dexamethasone on the re-excretion pattern of infectious bovine rhinotracheitis virus and humoral immune response. Veterinary Microbiology 1979, 4, 149-155.
2. Homan, E.J. and Easterday, B.C. Isolation of bovine herpesvirus-1 from trigeminal ganglia of clinically normal cattle. American Journal of Veterinary Research 1980, 41, 1212-1213.
3. Ackermann, M. and Wyler, R. The DNA of an IPV strain of bovid herpesvirus 1 in sacral ganglia during latency after intravaginal infection. Veterinary Microbiology 1984, 9, 53-63.
4. Van Engelenburg, F.A.C., Van Schie, F.W., Rijsewijk, F.A.M. and Van Oirschot, J.T. Excretion of bovine herpes virus 1 in semen is detected much longer by PCR than by virus isolation. Journal of Clinical Microbiology 1995, 33, 308-312.
5. Bitsch, V. Infectious bovine rhinotracheitis virus infection in bulls, with special reference to preputial infection. Applied Microbiology 1973, 26, 337-343.
6. Pastoret, P.P., Thiry, E., Brochier, B., Derboven, G. and Vindevogel, H. The role of latency in the epizootiologgy of infectious bovine rhinotracheitis. In: Latent Herpesvirus Infections in Veterinary Medicine (Eds Wittmann, G., Gaskell, R.M. and Rziha, H.J.)-Martinus Nijhoff, The Hague, 1984, pp. 211-229.
7. Sheffy, B.E. and Rodman, S. Activation of latent infectious bovine rhinotracheitis infection. Journal of the American Veterinary Medical Association 1973, 163, 850-851.
8. Pastoret, P.P., Babiuk, L.A., Misra, V. and Griebel, P. Reactivation of temperature-sensitive and non temperature-sensitive infectious bovine rhinotracheitis vaccine virus with dexamethasone. Infection and Immunity 1980, 29, 483-488.
9. Hage, J.J., Schukken, Y.H., Barkema, H.W., Benedictus, G. and Wentink, G.H. Population dynamics of BHV1 infection in a dairy herd. Veterinary Microbiology 1996, 53, 169-180.
10. Frerichs, G.N., Woods, S.B., Lucas, M.H. and Sands, J.J. Safety and efficacy of live and inactivated infectious bovine rhinotracheitis vaccines. Veterinary Record 1982, 111, 116-122.
11. Wyler, R., Engels, M. and Schwyzer, M. Infectious bovine rhinotracheitis/vulvovaginitis (BHV1). In Herpesvirus Diseases of Cattle, Horses, and Pigs (Ed. Wittmann, G.). Kluwer, Boston, 1989, pp. 1-72.
12. Bruchhof, B.R. and Straub, O.C. BHV-1 Reaktivierung nach verschiedenen Infektions-und Vakzinierungsarten. Tierärztliche Umschau 1993, 48, 503-508.
13. Kaashoek, M.J., Moerman, A., Madic, A., Rijsewijk, F.A.M., Quak, J., Gielkens, A.L.J. and Van Oirschot, J.T. A conventionally attenuated gE-negative strain of bovine herpesvirus type 1 is an efficacious and safe vaccine. Vaccine 1994, 12, 439-444.
14. Meyer, H., Mayr, A., Bachmann, P.A., Bernardi, G. and Wagner, H. Schutzimpfung von latent IBR-IPV Virus infizierten Bullen mit einer Vakzine aus inaktiviertem IBR-Virus. Tierärztliche Umschau 1985, 40, 974-985.
15. Thiry, E. and Lemaire, M. Vaccination with bovine herpesvirus 1 inactivated vaccine cannot be considered as a stimulus of reactivation. In Proceedings of the XIX World Buiatrics Congress, Edinburgh, 8-12 July 1996, pp. 45-48.
16. Vandeputte, J., Brun, A., Lacoste, F. and Saint-Marc, B. Glycoprotein vaccine against IBR: effect of vaccination on latency (recrudescence after challenge exposure). In Proceedings of XVII World Buiatrics Congress, USA, 1992, 1, 171-175.
17. Forschner, E., Bünger, I., Seidler, M., Peters, E., Rienhoff, E., Vogel, R., Hitzmann, G., Dietze, H., Happich, A. and Kälher, W. BHV1 Infektion der Rinder: Sanierung durch aktive Immunisierung seropositiver Tiere mit inaktiviertem Impfstoff, ein Feldversuch. Deutsche Tierärztliche Wochenschrift 1987, 94, 429-433.
18. Van Oirschot, J.T., Kaashoek, M.J., Rijsewijk, F.A.M. and Stegeman, J.A. The use of marker vaccines in eradication of herpesviruses. Journal of Biotechnology 1996, 44, 75-81.
19. Kaashoek, M.J., Moerman, A., Madic, J., Weerdmeester, K., Maris-Veldhuis, M., Rijsewijk, F.A.M. and Van Oirschot, J.T. An inactivated vaccine based on a glycoprotein E-negative strain of bovine herpesvirus 1 induces protective immunity and allows serological differentiation. Vaccine 1995, 13, 342-346.
20. Van Drunen Littel-van den Hurk, S., Van Donkersgoed, J., Kowalski, J., van den Hurk, J.V., Harland, R., Babiuk, L.A. and Zamb, T.J. A subunit gIV vaccine, produced by transfected mammalian cells in culture, induces mucosal immunity against bovine herpesvirus-1 in cattle. Vaccine 1994, 12, 1295-1302.
21. Stanberry, R.L., Bernstein, D.I., Burke, R.L., Pachl, C. and Myers, M.G. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. Journal of Infectious Diseases 1987, 155, (5), 914-920.
22. Straus, S.E., Corey, L., Burke, R.L., Savarese, B., Barnum, G., Krause, P.R., Kost, R.G., Meier, J.L., Sekulovich, R., Adair, S.F. and Dekker, L.C. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 1994, 343, 1460-1463.
23. Nesburn, A.B., Burke, R.L., Ghiasi, H, Slanina, S., Bahri, S. and Wechsler, S.L. Vaccine therapy for ocular herpes simplex virus (HSV) infection: periocular vaccination reduces spontaneous ocular HSV type 1 shedding in latently infected rabbits. Journal of Virology 1994, 68, 5084-5092.
24. Kaashoek, M.J., Straver, P.J., van Rooy, E.M.A., Quak, J. and Van Oirschot, J.T. Virulence and immunogenicity and reactivation of seven bovine herpesvirus 1.1 strains: clinical, virological and hematological aspects. Veterinary Record 1996, 139, 416-421.
25. Statistix Analytic Software, Tallahassee, USA.
26. Kaashoek, M.J. and Van Oirschot, J.T. Early immunity induced by a live gE-negative bovine herpesvirus 1 marker vaccine. Veterinary Microbiology 1996, 53, 191-197.
27. Bosch, J.C., Kaashoek, M.J., Kroese, A.H. and Van Oirschot, J.T. An attenuated bovine herpesvirus 1 marker vaccine induces a better protection than two inactivated marker vaccines. Veterinary Microbiology 1996, 52, 223-234.
28. Van Engelenburg, F.A.C., Kaashoek, M.J., Van Oirschot, J.T. and Rijsewijk, F.A.M. A glycoprotein E deletion mutant of bovine herpesvirus 1 infects the same limited number of tissues in calves as wild-type virus, but for a shorter period. Journal of General Virology 1995, 76, 2387-2393.
29. Straub, O.C. Experiences with two BHV1 marker vaccines. In Proceedings of the XIX World Buiatrics Congress, Edinburgh, 1996, 1, 39-41.
30. Campos, M., Godson, D.L., Hughes, H.P.H. and Babiuk, L.A. Cytokine applications in infectious diseases. In: Cell-mediated Immunity in Ruminants (Eds Goddeeris, B. and Morrisson, I.). CRC Press, Boca Raton, 1994, pp. 229-240.
31. Bosch, J.C., de Jong, M.C.M., Maissan, J. and van Oirschot, J.T. Quantification of experimental transmission of bovine herpesvirus 1 in cattle vaccinated with marker vaccines. Proceedings of a Symposium: IBR and Other Ruminant Herpesvirus Infections, Liège, 1995, 51.